Benefits of an Herbal-amino Acid Supplement in Osteoarthritis: Results of a Randomized Double-Blind Placebo Controlled Trial

Science Press Release Distribution Services

Benefits of an Herbal-amino Acid Supplement in Osteoarthritis: Results of a Randomized Double-Blind Placebo Controlled Trial

May 11, 2021 Microbiology and Biotechnology 0

Osteoarthritis is the most common form of joint disease, and it is characterised by chronic inflammation that can lead to joint damage, including the degradation of articular cartilage and the exposure of underlying bone, over time. A medicinal plant and L-leucine mixture (HLM) was studied in subjects with proven osteoarthritis of the knee in a multi-center, randomised, placebo-controlled, double-blind clinical trial. A total of 96 osteoarthritic subjects were enrolled and randomly assigned to one of two treatment groups: placebo (n = 38) or HLM (n = 38). Uncaria tomentosa (300 mg), Boswellia serrata (200 mg), Lepidium meyenii (1000 mg), and L-Leucine (700 mg) were given once a day to the HLM community. Capsules containing carboxymethylcellulose were given to the placebo group. The eight-week therapy included tests on days seven, fourteen, twenty-eight, and fifty-six. The main target was to reduce the overall WOMAC ranking. VAS pain, tolerability, investigator evaluations, use of rescue medication (acetominophen), as well as vital sign and laboratory assessments, were all included in the study. In terms of age, gender, and disease severity, subject randomization worked well. The placebo group had 32/38 subjects completing the experiment, while the HLM group had 35/38. Over the course of the 8-week trial, both groups’ WOMAC scores (pain, stiffness, physical performance, and total) decreased gradually, but the magnitude was significantly greater in HLM (P 0.05). HLM reduced total WOMAC by 46.5 percent, while placebo reduced it by 25.4 percent. In the placebo community, VAS pain was decreased by 21.8 percent (p 0.002), but with HLM therapy, the improvements were substantially greater (37.8 percent, p 0.03).

HLM received a score of 24/35 (69%) from the investigator, while placebo received a score of 14/32 (44%) (P = 0.05). HLM and placebo had similar levels of rescue drug intake and tolerability. These properties of HLM prompted a clinical inquiry into its potential as an osteoarthritis treatment, which is the subject of this article. Neither party was concerned about their safety. Despite the fact that there was a placebo impact, HLM was obviously more successful in alleviating osteoarthritis symptoms. This HLM is a novel, healthy, and reliable way to manage osteoarthritis symptoms.

Author (s) Details

Mark J. S. Miller
Kaiviti Consulting, LLC, Dallas, Texas, USA.

View Book :- https://stm.bookpi.org/RPMB-V5/article/view/864

 

Leave a Reply

Your email address will not be published. Required fields are marked *